ReachMD CME

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/importance-benefits-of-early-diagnosis/14649/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/how-to-make-an-early-diagnosis/14650/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-biomarkers-in-alzheimers-disease/14651/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/standard-of-care/14652/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/pathology-amyloid-vs-tau/14653/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/what-is-immunotherapy/14654/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/differences-among-agents/14655/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/additional-treatments-for-alzheimers-disease/14656/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/prevention-of-alzheimers-disease/14657/ TBD

CME credits: 1.00 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/clinical-trials-in-alzheimers-disease/14658/ TBD

CME credits: 0.50 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/transforming-cervical-cancer-screening-and-management-new-guidelines-new-tests-a-case-based-discussion/14676/ Experts discuss the ACS and ASCCP CCV screening guidelines and review the benefits of primary screening and the latest data driven testing options. Is Pap cytology a thing of the past? Find out more about harmonization of guidelines from leading experts, Drs. Cantrell, Stoler and Huh. You might just transform your clinical practice.

CME credits: 0.25 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/tentative-approval-understanding-the-fda-ruling-on-once-nightly-sodium-oxybate/14688/ While most clinicians are aware of a drug being either “approved” or “not approved” by the FDA, many are not familiar with the term “tentative approval.” Leading experts, attorney Sara Koblitz, JD, and Dr. Michael Thorpy, review the FDA approval process, explore how “tentative approval” is currently impacting treatment in the field of sleep medicine, and discuss how “non-drug” issues are related to delayed FDA approval. Review the latest safety and efficacy pivotal trial data associated with once-nightly sodium oxybate and find out if we're truly on the cusp of a new awakening in sleep medicine.

CME credits: 0.25 Valid until: 30-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/talking-rare-epidemiology-and-pathogenesis-of-apol1-mediated-kidney-disease/14781/ End-stage kidney disease (ESKD) is at least 3x higher among African Americans compared to Americans of European descent. Carriers of APOL1 variants with chronic kidney disease (CKD) are associated with more rapid disease progression and an increased risk of kidney failure. Join Drs. Martin Pollak and Susanne Nicholas as they discuss the epidemiology and possible mechanisms of APOL1 kidney disease, as well as recent clinical evidence for therapies in development that can potentially prevent rapid disease progression.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-neutropenia-of-the-fetus-and-newborn/13910/ Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology Neonatal alloimmune neutropenia (NAIN or NIN) is a neutrophil blood group antagonism similar to HDFN and FNAIT. Its presentation varies clinically and ranges from asymptomatic to severe manifestations such as sepsis and meningitis. Listen in as Drs. Masja de Haas and Lee Shulman discuss clinical clues that should catch your eye. Discover novel yet simple ways to be vigilant and make the right clinical calls.

CME credits: 0.25 Valid until: 29-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-bone-health-in-postmenopausal-post-fracture-patients/14662/ Life-altering secondary fractures are a harsh reality, but Medicare studies show, and orthopedic surgeons agree, that knowledge has not translated into prevention. Why is there clinical inertia in providing preventative interventions related to secondary fragility fractures? Join Drs. Andrea Singer and Susan Bukata as they provide a cogent medical approach to preventing these fractures and a roadmap for when and how to use available therapies based on their mechanisms of action.

CME credits: 0.25 Valid until: 27-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/expert-answers-to-common-questions-about-met-exon-14skipping-mutations-in-nsclc/14678/ Non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and research has evolved its diagnosis and treatment through the discovery of genetic alterations and molecular pathways, personalizing treatment based on tumor mutation(s). The molecular characterization of tumors using techniques such as next-generation sequencing (NGS) has expanded the understanding of actionable molecular alterations, and in tandem has accelerated the development of drugs to inhibit alterations with greater specificity, leading to the development of novel target-selected agents in NSCLC. The NCCN Guidelines strongly advise assessment of at least 8 targets for NSCLC by NGS, including MET exon 14–skipping mutations (METex14). The FDA has approved two MET inhibitors, capmatinib and tepotinib, for patients with METex14 metastatic NSCLC, and there is ongoing research for other targeted agents. Studies have established that treatment with MET-targeted therapies improves outcomes in patients with METex14, as opposed to patients receiving chemotherapy and/or immunotherapy, which generate a modest activity response. AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer to verify where clinical practice gaps exist. That's why this activity will …

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-standards-and-future-opportunities-for-adcs-in-advancedmetastatic-triple-negative-breast-cancer/14551/ Antibody-drug conjugates have transformed the treatment of triple-negative breast cancer (TNBC). Tune in to hear about approved ADCs and others in development and find out where they fit into the NCCN Guidelines for TNBC.

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/current-and-emerging-roles-of-immunotherapy-and-adcs-for-patients-with-non-muscle-invasive-and-muscle-invasive-bladder-cancer/14553/ Do you know how to best utilize immunotherapy and antibody-drug conjugates to improve treatment outcomes in your patients with metastatic urothelial cancer? Listen in as Drs. Mamta Parikh and Daniel Petrylak break down the data surrounding these therapies so you can improve the care you provide.

CME credits: 0.50 Valid until: 05-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/selecting-and-sequencing-immunotherapies-for-patients-with-advanced-rcc/14554/ Do you know how to best utilize immunotherapy to improve treatment outcomes in your patients with metastatic renal cell cancer? Listen as Drs. Eric Jonasch and Bradley McGregor discuss the data and guidelines surrounding selecting and sequencing immunotherapy for your patients.

CME credits: 0.50 Valid until: 21-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/utilization-and-management-of-antibody-drug-conjugates-in-metastatic-breast-cancer-the-relationship-between-adcs-and-her2/14552/ New data for sequencing antibody-drug conjugates (ADCs) in HER2 metastatic breast cancer have hit the conference circuit. Listen as Drs. William Gradishar, Javier Cortés, and Hope Rugo dissect the data surrounding ADCs in different types of HER2 metastatic breast cancer. Make sure you're up to date and offering your patients the best care.

CME credits: 0.50 Valid until: 20-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/treating-iron-deficiency-in-patients-with-hfref-a-review-of-the-recent-data-for-iv-iron-replacement-therapy/13508/ Symptoms from iron deficiency can greatly affect the overall quality of life of our patients with heart failure. Recent clinical evidence from the IRONMAN trial explores the use of IV iron replacement in patients with chronic heart failure. Join Drs. Javed Butler, Stefan Anker, Piotr Ponikowski, and Robert Mentz as they discuss the clinical trial design and outcomes from IRONMAN compared to the current body of evidence for managing iron deficiency in this setting.

CME credits: 0.25 Valid until: 20-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/improving-outcomes-in-patients-with-ovarian-cancer-multidisciplinary-patient-centered-care/14565/ Follow along as Dr. Floortje Backes walks us through a patient case and demonstrates the shared decision-making process of selecting an appropriate maintenance treatment regimen for advanced ovarian cancer.

CME credits: 1.00 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/when-to-start-using-sglt2i-in-hfref-initiating-guideline-recommended-treatment-options/14735/ What are the benefits of SGLT2 inhibitors (SGLT2i) in heart failure? What clinical challenges can physicians face when initiating guideline recommended therapy in heart failure? And what unanswered questions with SGLT2i in heart failure remain? Three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure. This course consists of the following: The clinical challenges of initiating guideline recommended therapy in HF - Prof. John McMurray, MD - Glasgow, UK Benefits and evolving insights on SGLT2i in the spectrum of LVEF - Prof. Carolyn Lam, MD, PhD - Singapore Expanding evidence on SGLT2i: Where are we now and what can we expect? - Prof. Scott Solomon, MD - Boston, MA, USA

CME credits: 1.00 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/clinical-dilemmas-in-heart-failure-weighing-the-balance-of-raasi-and-hyperkalemia/14740/ Optimizing RAASi therapy in patients with heart failure, while managing hyperkalemia can be challenging. Three experts talk about this clinical dilemma and present new therapeutic options that could achieve better outcomes in patients with heart failure. This course consists of the following: Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure - Prof. Andrew Coats, MD - Coventry, UK Hyperkalemia in heart failure: Why should we care? - Clara Bonanad Lozano, MD, PhD - Valencia, Spain Potassium binding as RAASi enabling therapy: applying recent insights into practice - Aaron Wong, MD - Bridgend, UK

CME credits: 1.00 Valid until: 19-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/innovative-therapeutic-approaches-in-hypertrophic-cardiomyopathy/14744/ Hypertrophic cardiomyopathy (HCM) is more than just a thickened heart. This series of three presentations provides insights into the etiology and pathogenesis of this complex disease, how to make the diagnosis, and the therapeutic options. Dr. Antonis Pantazis starts his presentation off with a scientific definition of HCM and explains what distinguishes it from other conditions that feature a “thick heart.” Dr. Michelle Michels highlights the importance of a thorough work-up in patients with LV hypertrophy to make the correct diagnosis. Prof. Iacopo Olivotto discusses the study results of mavacamten, a drug specifically designed for treating HCM. This course consists of the following: Unhiding hypertrophic cardiomyopathy, a call for action - Antonis Pantazis, MD - London, UK Hypertrophic cardiomyopathy: making the diagnosis - Michelle Michels, MD, PhD - Rotterdam, the Netherlands Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape? - Prof. Iacopo Olivotto, MD - Florence, Italy

CME credits: 0.25 Valid until: 14-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-endometriosis-gnrh-antagonists/14145/ Are you currently considering GnRH antagonists as first-line therapy, or are you waiting for patients to fail other endometriosis treatment approaches first? Drs. Andrea Lukes and Lee Shulman discuss how the advent of effective GnRH antagonists is evolving the care of endometriosis. Are you ready to provide patients with the clinical outcomes they seek while balancing the benefits of medical and surgical approaches?

CME credits: 0.75 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-updates-in-diagnostic-therapeutic-and-prognostic-strategies/14035/ The management of inflammatory bowel disease (IBD) remains challenging, owing to variable clinical presentations and ever-changing therapeutic options. In this interactive CME activity, Dr. Sushila Dalal presents the case of a newly diagnosed patient with IBD, highlighting the importance of prompt diagnosis and aggressive medical treatment. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of IBD and learn more from IBD expert faculty.

CME credits: 0.75 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/virtual-ibd-clinic-surgical-and-pharmacological-therapeutics/14036/ It is estimated that only 20% to 30% of patients with Crohn's disease (CD) have a non-progressive or indolent course. While most patients with CD present with non-penetrating or non-stricturing disease, 50% of patients develop intestinal complications within 20 years of diagnosis. In this interactive CME activity, Dr. Sauk presents the case of a patient with CD, highlighting the importance of early recognition of disease complications and considerations for surgical management. This real-world patient case offers you an opportunity to test your clinical skills for the successful management of inflammatory bowel disease (IBD) and learn more from an IBD expert faculty.

CME credits: 0.50 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/prognostic-tools-in-the-management-of-adpkd/13877/ This Expert Exchange webcast is designed to help improve clinicians' ability to utilize prognostic tools to monitor disease progression and implement appropriate treatment strategies in patients with ADPKD.

CME credits: 0.75 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-medical-management-of-uterine-fibroids-achieving-patient-centered-goals-and-outcomes/14458/ By the age of 50, ultrasound imaging demonstrates that 70%-80% of women have fibroids. Uterine fibroids are associated with disability similar to other chronic diseases. They can even lead to lower vitality and social function than are experienced by women with breast cancer. Fibroid-related hysterectomies account for 45% of all US hysterectomies, but a surgical approach is no longer one size fits many. Join Dr. Andrew Kaunitz as he describes the clinical presentations of fibroids and how newly emergent medical options greatly improve fibroid-related symptoms, provide time to consider other alternatives, and can be used to bridge the transition to menopause.

CME credits: 0.50 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/mental-health-and-menopause-patient-centric-approaches/14477/ Optimizing the management of comorbid depression and menopause is a significant clinical challenge. When the darkness begins to set in, are you able to hear your patients' needs and deliver life-changing treatment? Join Dr. Jennifer Payne as she provides concrete tips and explores the latest guidelines and research on therapies that improve vasomotor symptoms, mood, and perimenopausal depression. Get ready to offer new hope to your patients as you help them cool off and begin to see the dawn of a new day.

CME credits: 0.75 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/endoshare-2022-a-patient-centered-evidence-based-approach-to-managing-endometriosis-pain/14478/ Endometriosis is challenging to diagnose, with approximately 6 to 11 years from symptom onset to definitive diagnosis and treatment. Many medical providers are not adequately familiar with the disease, and this, coupled with historically limited medical options, has resulted in surgical approaches often being considered as the first treatment option. Join us as Dr. Hugh Taylor discusses how this landscape is changing to one in which safe and effective medical options can now offer improved outcomes for our patients with endometriosis.

CME credits: 0.75 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/lets-discuss-postpartum-depression-screening-diagnosis-and-management/14600/ This animated Women's Health 2022 lecture features a discussion between Drs. Jennifer Payne and Anita Clayton who clearly highlight the importance of screening for perinatal and postpartum depression (PPD). Our experts delve into the critical importance of proactively diagnosing and treating women during the various stages of pregnancy and review the latest therapies that specifically target PPD. Find out how these therapies compare to traditional antidepressants and how PPD treatment can improve the health and quality of life for patients and their families. What changes can you implement into your clinical practice to improve maternal and infant health?

CME credits: 0.50 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/spanning-the-spectrum-of-vvc-diagnosing-and-managing-acute-and-recurrent-disease/14660/ For affected women, acute vulvovaginal candidiasis (VVC) brings with it a significant health burden, and the substantial morbidity and poor quality of life associated with recurrent disease (RVVC) requires improved diagnosis, management, and quality of care. Join Dr. Michael Krychman as he dissects the barriers to managing VVC and RVVC and provides insights on diagnosis and management based on guidelines, plus an overview of innovative therapeutic agents. The unique qualities of the current and emerging therapeutic interventions may well represent a significant step forward in how you manage these challenging infections.

CME credits: 0.50 Valid until: 12-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/long-acting-reversible-contraceptives-their-critical-role-in-addressing-todays-reproductive-health-landscape/14661/ Intrauterine devices and contraceptive implants, also called long-acting reversible contraceptives (LARCs), are the most effective reversible contraceptive methods. The major advantage of LARCs compared with other reversible contraceptive methods is that they do not require ongoing effort on the part of the patient for long-term, effective use. In addition, after the device is removed, the return of fertility is rapid. Join Dr. David Eisenberg has he discusses when LARCs should be recommended as a first-line contraceptive choice and when they should not. He further details how to approach a shared decision-making discussion with patients about their contraceptive options.

CME credits: 0.25 Valid until: 06-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/hemolytic-disease-of-the-fetus-and-newborn-hdfn-what-pediatric-providers-need-to-know-when-managing-hemolytic-disease-in-newborns-hdn/13799/ What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.

CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/fatty-liver-or-nash-the-future-of-noninvasive-diagnosis-and-assessment/13651/ The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.

CME credits: 0.25 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-treatment-of-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-enhancing-antitumor-activity-through-inhibitor-of-apoptosis-protein-antagonism/14129/ There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.

CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-care-for-patients-with-advanced-hepatocellular-carcinoma-current-standards-and-future-directions-with-immunotherapy/14482/ Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?

CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/establishing-the-role-of-immunotherapy-in-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-endometrial-cancer/14459/ Are you testing for MSI-H/dMMR in your patients with advanced endometrial cancer? Listen in as Drs. Robert Coleman, Susana Campos, and Ana Oaknin break down the progress being made in biomarker testing and immunotherapy treatment for these patients.

CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/employing-immunotherapy-and-adcs-in-advanced-endometrial-and-cervical-cancers-current-and-emerging-therapies/14460/ The recent addition of immunotherapy to our armamentarium for endometrial and cervical cancer has shifted the treatment landscape. Listen in as Drs. Robert Coleman, Susana Campos, and Domenica Lorusso discuss innovations in immunotherapy and what role antibody-drug conjugates (ADCs) play in this setting.

CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-current-and-future-role-of-immuno-oncologic-agents-in-early-stage-locally-advanced-and-metastatic-nsclc/14493/ Immuno-oncologic agents have changed the treatment landscape for non-small cell lung cancer. Listen in as Drs. Debora Bruno, Gilberto Lopes, and Solange Peters discuss the most recent data for immunotherapy in early-stage, locally advanced, and metastatic NSCLC.